HUMA - Why Is Clinical-Stage Biotechnology Platform Company Humacyte Stock Gaining Friday? | Benzinga
Humacyte, Inc. (NASDAQ:HUMA) shares are trading higher on Friday.
The company announced that the U.S. FDA has accepted and granted Priority Review to Humacyte’s Biologics License Application (BLA) seeking approval of the Human Acellular Vessel (HAV).
HAV is used in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated and when autologous vein use is not feasible.
“We are very pleased that the FDA has accepted our BLA and has recognized ...